Emcure

Ref: EPL/CS/SE/0016/2025 **Date:** February 26, 2025

To,

National Stock Exchange of India Limited **Exchange Plaza, C-1, Block G,** **Bandra Kurla Complex, Bandra (East),** **Mumbai – 400 051** **Script Symbol: EMCURE**	**BSE Limited** **P J Towers,** **Dalal Street,** **Mumbai - 400 001** **Scrip Code/Symbol: 544210/ EMCURE**

Dear Sir/Madam,

Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") – US FDA inspection at API manufacturing facility located at Kurkumbh, Pune, Maharashtra, India

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the United States Food and Drug Administration ("US FDA") had conducted a current Good Manufacturing Practices ('cGMP') inspection of Company's API manufacturing facility located at M.I.D.C., Kurkumbh, Taluka - Daund, Pune – 413802, Maharashtra, from February 19, 2025 to February 25, 2025. On conclusion of the inspection, the Company received two observations in Form 483.

We are addressing the observations comprehensively and will respond to the US FDA within the stipulated timeframe.

You are requested to take the above information on your records.

Thanking you,

For **Emcure Pharmaceuticals Limited**

SHARMA CHETAN RAJENDRA
Digitally signed by SHARMA CHETAN RAJENDRA
Date: 2025.02.26 11:38:36 +05'30'

Chetan Sharma
Company Secretary & Compliance Officer
Membership Number: F8352